TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06613789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b
Description: self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b
Description: self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 426c.Mod.Core-C4b
Description: self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum
Study: NCT06005142

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Eriomin
Description: Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Washout
Description: After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Washout
Description: After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
Study: NCT06613789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3M-052-AF
Description: 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide suspension (Alum)
Description: Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide suspension (Alum)
Description: Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide suspension (Alum)
Description: Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum hydroxide suspension (Alum)
Description: Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Diluent
Description: Tris-NaCl buffer.
Study: NCT06615128

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: blood sample to detect sCD25 from systemic sclerosis and Healthy control.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: blood sample to detect sCD25 from systemic sclerosis and Healthy control.
Study: NCT06005142

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
Study: NCT06521658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timing of retroflexion
Description: The intervention is the timing of the retroflexion/looping of the colonoscope in the rectum
Study: NCT05610774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
Study: NCT05802173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-105795, 0.0025%
Description: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-105795, 0.02%
Description: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDM-105795 topical vehicle solution
Description: The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Study: NCT06434649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrafascial robotic assisted radical prostatectomy via posterior approach
Description: Extrafascial robotic assisted radical prostatectomy via posterior approach will be applied in the intermediate or high risk patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extrafascial robotic assisted radical prostatectomy via anterior approach
Description: Extrafascial robotic assisted radical prostatectomy via anterior approach will be applied in the intermediate or high risk patients.
Study: NCT06613802

Intervention type: OTHER
Intervention: Time
Description: This is a cross sectional study, and the exposure where the outcome is expected to change by is time. Years included in the study are 2013-2014, 2018-2019 and 2023

Intervention type: OTHER
Intervention: Time
Description: This is a cross sectional study, and the exposure where the outcome is expected to change by is time. Years included in the study are 2013-2014, 2018-2019 and 2023

Intervention type: OTHER
Intervention: Time
Description: This is a cross sectional study, and the exposure where the outcome is expected to change by is time. Years included in the study are 2013-2014, 2018-2019 and 2023
Study: NCT06614075

Intervention type: BEHAVIORAL
Intervention: Questionnaire and anthropometric measurement
Description: Questionnaire including sociodemographic characteristics, lifestyle habits, body weight, height, dietary assessment and diabetes risk; Anthropometric measurement including waist circumference
Study: NCT06685276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: 5mg qd, po, 2 weeks on/1 week off, q3w, or 3mg qd, po, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg, iv, d1, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide: 30mg/m2, po, biw.
Study: NCT06684743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV prefusion F protein-based vaccine
Description: For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
Study: NCT06692556

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant radiotherapy
Description: Patients will receive an adjuvant radiotherapy corresponding to an equivalent dose of 45 to 50 Gy (Equivalent Dose in 2 Gy Fractions \[EQD2\] with a tumor alpha/beta ratio of 10 Gy) delivered on the operating bed.~Patients will be treated by :~* either external radiation therapy using high-energy electrons or photons:~  * 45 Gy in 15 fractions of 3 Gy~ * 50 Gy in 25 fractions of 2 Gy~* or interstitial brachytherapy or brachytherapy via skin applicators:~  * 36 Gy in 8 fractions of 4.5 Gy~ * 36 Gy in 9 fractions of 4 Gy~ * 40 Gy in 8 fractions of 5 Gy~Radiation therapy should be started within 8 weeks after surgery (or 10 if delayed healing).~Patients will be monitored regularly until the date of the first relapse (local, regional or metastatic), or until the date of death (if no relapse).~Regardless of the type of relapse, remedial treatments will be left to the the investigator's discretion up to the first metastatic relapse.
Study: NCT06693882

Intervention type: DEVICE
Group type: OTHER
Intervention: EYETRONIC Nextwave System
Description: Eyetronic Nextwave is a neurostimulation device that stimulates the optic nerve non-invasively using transcranial alternating current stimulation delivered through goggles in patients presenting with glaucoma.~Eyetronic is approved in Europe for the treatment of glaucoma to possibly delay progression of visual field (VF) loss for at least 12 months. The indication for use in Europe includes all patients suffering from neuropathies of the optic nerve resulting in loss of VF. Two studies conducted in Europe have demonstrated improvement in visual fields following 10-days of optic nerve stimulation treatment with this device. In the current study, the Eyetronic system will be used to treat only those individuals who have visual field loss from glaucoma.
Study: NCT05416749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8MW2311
Description: All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
Study: NCT05488782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAM-Red
Description: Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: After the week 12 follow up visits subjects in the Waitlist group will receive the TEAM Red intervention
Study: NCT06161948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted enteral nutrition therapy group
Description: Control the daily enteral nutrition time to 8-12 hours, enteral nutrition start time: 06:00 \~ 08:00, end time: 16:00 \~ 18:00. Enteral nutrition lasts until the patient discontinues enteral nutrition, the patient dies, the patient is transferred from the ICU, or enteral nutrition is used until 28 days, whichever event occurs first.

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous enteral nutrition control group
Description: The control group was continuous enteral nutrition (24 hours), which lasted until the patient stopped taking enteral nutrition, the patient died, the patient was transferred from the ICU, or enteral nutrition was used until 28 days, whichever event occurred first.
Study: NCT05283928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoDensification (OD) protocol
Description: Osseodensification is a drilling process by which bone is being compacted and auto-grafted in an outwardly expanding direction from the osteotomy. When the osseodensification drills are being rotated in a reversed, non-cutting direction a strong and dense layer of bone is formed along the walls and base of the osteotomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard drilling (SD) protocol (NobelReplace® Conical)
Description: osteotomy preparation through bone excavation is necessary in implant site development for the placement of dental implants. The process involves a forward cutting process with removal of bone tissue creating appropriate size osteotomy for the dental implant.
Study: NCT06272669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Description: For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
Study: NCT05616026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 6 months of diabetes management support via SMS texts including reminders for medication adherence, appointments, and diabetes self-care activities as well as education, and support
Study: NCT06272669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Description: For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.

Intervention type: DEVICE
Group type: OTHER
Intervention: Active-tDCS
Description: For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham-tDCS
Description: For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham-tDCS
Description: For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
Study: NCT06163937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed fruit juice
Description: Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study: NCT06394492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: SHR-A1921 dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel dose 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan dose 4
Study: NCT06358963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive 30 mg of Coq10
Description: Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Medicare Drugs
Description: and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Medicare Drugs
Description: and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Medicare Drugs
Description: and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
Study: NCT05645315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection and TQB2450 injection
Description: TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
Study: NCT06693934

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Joint Asia Diabetes Evaluation (JADE) assessment
Description: Participants found to have diabetes on OGTT will undergo annual JADE assessment which include eye/foot/urine/blood tests with issue of a personalized JADE report. The JADE Program is a quality improvement program to improve self management and inform shared decision making between doctor and patient.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education webinars, workshops and health messages
Description: All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education webinars, workshops and health messages
Description: All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education webinars, workshops and health messages
Description: All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education webinars, workshops and health messages
Description: All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.
Study: NCT06695858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESPB
Description: Patients received bilateral ultrasound-guided ESPB using 20 mL bupivacaine 0.25% on each side.
Study: NCT06395688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one
Description: AEF0117 soft capsules of 1mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo soft capsules (identical to active compound)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo soft capsules (identical to active compound)
Study: NCT05662397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST-1011
Description: HST-1011 given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST-1011
Description: HST-1011 given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST-1011
Description: HST-1011 given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST-1011
Description: HST-1011 given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally
Study: NCT05760612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and nelatinib
Description: Postoperative adjuvant treatment, for about 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab and Parstuzumab
Description: Postoperative adjuvant treatment, for about 1 year
Study: NCT06574165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training
Description: 6-week structured exercise intervention. The intervention will include twice weekly, center-based, aerobic exercise consisting of continuous treadmill walking. Each center-based session will include 45 minutes of aerobic exercise in addition to balance and flexibility exercises to promote cool-down. During each exercise session, they will also be asked to wear a heart rate monitor to measure mean pulse during their exercise sessions.
Study: NCT06569251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg QD
Description: Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 6 mg BID
Description: Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme